{"id":9009,"date":"2026-03-06T13:02:59","date_gmt":"2026-03-06T13:02:59","guid":{"rendered":"https:\/\/blog.mygenericpharmacy.com\/?p=9009"},"modified":"2026-03-06T13:03:06","modified_gmt":"2026-03-06T13:03:06","slug":"deadly-brain-cancer-understanding-glioblastoma-and-the-fight-for-survival","status":"publish","type":"post","link":"https:\/\/blog.mygenericpharmacy.com\/index.php\/2026\/03\/06\/deadly-brain-cancer-understanding-glioblastoma-and-the-fight-for-survival\/","title":{"rendered":"Deadly Brain Cancer: Understanding Glioblastoma and the Fight for Survival"},"content":{"rendered":"\n<p><strong>Glioblastoma: Symptoms, Risks &amp; Treatment Guide<\/strong><\/p>\n\n\n\n<p>Learn about glioblastoma, an aggressive form of brain cancer. Discover its symptoms, causes, diagnosis, and treatment options to better understand this serious condition.<br><img loading=\"lazy\" decoding=\"async\" width=\"275\" height=\"251\" class=\"wp-image-9010\" style=\"width: 275px;\" src=\"https:\/\/blog.mygenericpharmacy.com\/wp-content\/uploads\/2026\/03\/Brain-Cancer.png\" alt=\"\" srcset=\"https:\/\/blog.mygenericpharmacy.com\/wp-content\/uploads\/2026\/03\/Brain-Cancer.png 548w, https:\/\/blog.mygenericpharmacy.com\/wp-content\/uploads\/2026\/03\/Brain-Cancer-300x274.png 300w, https:\/\/blog.mygenericpharmacy.com\/wp-content\/uploads\/2026\/03\/Brain-Cancer-296x270.png 296w\" sizes=\"auto, (max-width: 275px) 100vw, 275px\" \/><\/p>\n\n\n\n<p>When we talk about deadly brain cancer, we&#8217;re primarily talking about\u00a0<strong>glioblastoma multiforme (GBM)<\/strong>\u00a0\u2014the most aggressive and lethal form of <strong><a href=\"https:\/\/blog.mygenericpharmacy.com\/index.php\/category\/brain-disease\/\" target=\"_blank\" rel=\"noopener\" title=\"brain cancer\">brain cancer<\/a><\/strong> in adults. Accounting for approximately\u00a0<strong>45% of all primary malignant brain tumors<\/strong>, glioblastoma has a devastating prognosis that has remained stubbornly poor despite decades of research\u00a0<a href=\"http:\/\/www.nfcr.org\/cancer-types\/cancer-types-brain-cancer\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p>The statistics are sobering: the five-year survival rate for glioblastoma is only&nbsp;<strong>8%<\/strong>&nbsp;, and median survival after diagnosis is just&nbsp;<strong>14-18 months<\/strong>&nbsp;with standard treatment&nbsp;<a href=\"http:\/\/www.nfcr.org\/cancer-types\/cancer-types-brain-cancer\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/editora.univassouras.edu.br\/index.php\/RPU\/article\/view\/5182\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. In the United States alone, an estimated&nbsp;<strong>24,820 new cases<\/strong>&nbsp;of brain and other nervous system tumors will be diagnosed in 2025, with approximately&nbsp;<strong>18,330 deaths<\/strong>&nbsp;expected&nbsp;<a href=\"https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p>This article explores what makes <strong><a href=\"https:\/\/mygenericpharmacy.com\/category\/disease\/cancer\" target=\"_blank\" rel=\"noopener\" title=\"glioblastoma so deadly\">glioblastoma so deadly<\/a><\/strong>, current treatment approaches, and promising research that offers hope for better outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Makes Glioblastoma So Deadly?<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Aggressive Growth Pattern<\/h3>\n\n\n\n<p>Glioblastoma is classified as a&nbsp;<strong>Grade IV tumor<\/strong>&nbsp;by the World Health Organization (WHO)\u2014the highest grade possible. These tumors are characterized by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid proliferation:<\/strong>\u00a0GBM cells divide quickly and uncontrollably<\/li>\n\n\n\n<li><strong>Diffuse infiltration:<\/strong>\u00a0The tumor sends tentacle-like projections into surrounding brain tissue, making complete surgical removal nearly impossible<\/li>\n\n\n\n<li><strong>Extreme heterogeneity:<\/strong>\u00a0Even within a single tumor, cancer cells vary dramatically, making them moving targets for treatment\u00a0<a href=\"https:\/\/www.eurekalert.org\/news-releases\/1111479\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><strong>Angiogenesis:<\/strong>\u00a0GBM stimulates growth of new blood vessels to fuel its expansion<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Treatment-Resistant Nature<\/h3>\n\n\n\n<p>Several factors make GBM exceptionally difficult to treat:<\/p>\n\n\n\n<p><strong>The blood-brain barrier<\/strong>&nbsp;protects the brain from infection but also blocks many cancer drugs from reaching tumor cells&nbsp;<a href=\"https:\/\/www.drugtargetreview.com\/news\/192939\/organ-on-a-chip-tests-immune-wafer-for-glioblastoma\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. Even when drugs penetrate this barrier, GBM cells employ multiple resistance mechanisms to survive chemotherapy and radiation.<\/p>\n\n\n\n<p>The tumor microenvironment is described as&nbsp;<strong>immunologically &#8220;cold&#8221;<\/strong>&nbsp;\u2014it actively suppresses the immune system&#8217;s ability to recognize and attack cancer cells&nbsp;<a href=\"https:\/\/neurologytoday.aan.com\/doi\/full\/10.1097\/01.NT.0000554697.28994.18?ContribAuthorRaw=Moran%2C+Mark&amp;af=R&amp;ContribRaw=Moran%2C+Mark&amp;mi=4u1whn&amp;content=netod&amp;ConceptID=502182&amp;target=netod\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.drugtargetreview.com\/news\/192939\/organ-on-a-chip-tests-immune-wafer-for-glioblastoma\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. This explains why immunotherapies that revolutionized other cancers have struggled against GBM.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Molecular Complexity<\/h3>\n\n\n\n<p>GBM harbors numerous genetic mutations that influence treatment response. The most clinically relevant include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IDH1\/IDH2 mutations:<\/strong>\u00a0Present in some gliomas; patients with these mutations have better prognoses\u00a0<a href=\"https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><strong>MGMT promoter methylation:<\/strong>\u00a0Predicts better response to temozolomide chemotherapy<\/li>\n\n\n\n<li><strong>EGFRvIII mutation:<\/strong>\u00a0Occurs in 25-30% of GBM patients and is associated with treatment resistance\u00a0<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589004225016074\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><strong>1p\/19q codeletion:<\/strong>\u00a0Associated with better outcomes in certain glioma types\u00a0<a href=\"https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Recognizing the Signs: Symptoms of Brain Cancer<\/h2>\n\n\n\n<p>Symptoms depend on the tumor&#8217;s size and location but commonly include&nbsp;<a href=\"http:\/\/www.nfcr.org\/cancer-types\/cancer-types-brain-cancer\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.nuhs.edu.sg\/patient-care\/find-a-condition\/brain-cancer\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Headaches<\/strong>\u00a0(especially persistent or worse in the morning)<\/li>\n\n\n\n<li><strong>Seizures<\/strong>\u00a0(occurring in about 20% of patients at presentation and up to 70% over the disease course)<\/li>\n\n\n\n<li><strong>Nausea and vomiting<\/strong><\/li>\n\n\n\n<li><strong>Vision changes<\/strong>\u00a0(blurred vision, double vision)<\/li>\n\n\n\n<li><strong>Weakness or numbness<\/strong>\u00a0on one side of the body<\/li>\n\n\n\n<li><strong>Difficulty walking<\/strong>\u00a0or balance problems<\/li>\n\n\n\n<li><strong>Speech and language difficulties<\/strong><\/li>\n\n\n\n<li><strong>Memory loss and confusion<\/strong><\/li>\n\n\n\n<li><strong>Personality changes<\/strong><\/li>\n<\/ul>\n\n\n\n<p>If you experience any of these symptoms persistently, consult a healthcare provider immediately.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Current Treatment Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Standard of Care: The Stupp Protocol<\/h3>\n\n\n\n<p>For newly diagnosed GBM, the established treatment approach includes:<\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Maximal safe surgical resection:<\/strong>\u00a0Removing as much tumor as possible while preserving neurological function\u00a0<a href=\"https:\/\/www.nuhs.edu.sg\/patient-care\/find-a-condition\/brain-cancer\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><strong>Radiation therapy:<\/strong>\u00a0Typically 60 Gy delivered over 6 weeks<\/li>\n\n\n\n<li><strong>Temozolomide chemotherapy:<\/strong>\u00a0The only FDA-approved drug for GBM, given concurrently with radiation and then as maintenance therapy\u00a0<a href=\"https:\/\/editora.univassouras.edu.br\/index.php\/RPU\/article\/view\/5182\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n<\/ol>\n\n\n\n<p>Despite this aggressive approach, tumors nearly always recur.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Surgical Innovations<\/h3>\n\n\n\n<p><strong>Awake brain surgery (brain mapping)<\/strong>&nbsp;allows neurosurgeons to remove tumors near critical brain regions controlling speech, language, and movement. Patients remain awake during part of the procedure, providing real-time feedback that helps preserve vital functions&nbsp;<a href=\"https:\/\/www.nuhs.edu.sg\/patient-care\/find-a-condition\/brain-cancer\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p><strong>Supratotal resection<\/strong>&nbsp;\u2014removing more tissue than just the visible tumor\u2014has shown promising results in some studies&nbsp;<a href=\"https:\/\/editora.univassouras.edu.br\/index.php\/RPU\/article\/view\/5182\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Emerging Treatments<\/h3>\n\n\n\n<p><strong>Tumor Treating Fields (TTFields):<\/strong>&nbsp;This innovative therapy uses low-intensity electric fields to disrupt cancer cell division. It&#8217;s approved for both newly diagnosed and recurrent GBM and has shown improved survival when combined with temozolomide&nbsp;<a href=\"https:\/\/editora.univassouras.edu.br\/index.php\/RPU\/article\/view\/5182\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p><strong>Laser Interstitial Thermal Therapy (LITT):<\/strong>&nbsp;A minimally invasive technique that uses heat to destroy tumor cells, particularly useful for recurrent or hard-to-reach tumors&nbsp;<a href=\"https:\/\/editora.univassouras.edu.br\/index.php\/RPU\/article\/view\/5182\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Breakthrough Research: Hope on the Horizon<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Immunotherapy Advances<\/h3>\n\n\n\n<p>A groundbreaking 2019 study (with long-term follow-up reported in 2025) showed that administering the immunotherapy drug&nbsp;<strong>pembrolizumab (Keytruda) before surgery<\/strong>&nbsp;significantly improved survival in recurrent GBM patients&nbsp;<a href=\"https:\/\/neurologytoday.aan.com\/doi\/full\/10.1097\/01.NT.0000554697.28994.18?ContribAuthorRaw=Moran%2C+Mark&amp;af=R&amp;ContribRaw=Moran%2C+Mark&amp;mi=4u1whn&amp;content=netod&amp;ConceptID=502182&amp;target=netod\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<p><strong>Key findings:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Patients receiving neoadjuvant pembrolizumab had median survival of\u00a0<strong>13.9 months<\/strong>\u00a0versus\u00a0<strong>7.5 months<\/strong>\u00a0for those receiving it after surgery<\/li>\n\n\n\n<li>The pre-surgery approach allows T cells to recognize and attack a larger tumor burden, creating a broader and more durable immune response<\/li>\n\n\n\n<li>Tumors from the neoadjuvant group showed increased T-cell infiltration and suppression of cancer proliferation pathways\u00a0<a href=\"https:\/\/neurologytoday.aan.com\/doi\/full\/10.1097\/01.NT.0000554697.28994.18?ContribAuthorRaw=Moran%2C+Mark&amp;af=R&amp;ContribRaw=Moran%2C+Mark&amp;mi=4u1whn&amp;content=netod&amp;ConceptID=502182&amp;target=netod\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n<\/ul>\n\n\n\n<p>While experts caution that larger trials are needed before this becomes standard of care, the results represent one of the most promising advances in years.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Targeted Therapies for EGFRvIII-Positive GBM<\/h3>\n\n\n\n<p>For the 25-30% of GBM patients with EGFRvIII mutations, a 2025 network meta-analysis identified&nbsp;<strong>rindopepimut (a targeted vaccine) combined with bevacizumab<\/strong>&nbsp;as the most promising regimen for recurrent disease&nbsp;<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589004225016074\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. This combination showed the best outcomes for overall survival, progression-free survival, and objective response rate, with the lowest incidence of severe side effects.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Personalized Medicine Through AI<\/h3>\n\n\n\n<p>Researchers at Georgetown Lombardi Comprehensive Cancer Center have developed&nbsp;<strong>scFOCAL<\/strong>&nbsp;\u2014a computational framework that uses single-cell RNA sequencing to predict how individual tumors will respond to different treatments&nbsp;<a href=\"https:\/\/www.eurekalert.org\/news-releases\/1111479\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. This approach could eventually enable truly personalized therapy, identifying drug combinations tailored to each patient&#8217;s unique tumor cell populations.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Immune-Stimulating Wafers<\/h3>\n\n\n\n<p>Scientists at the University of Cincinnati are developing a&nbsp;<strong>delayed-release wafer<\/strong>&nbsp;containing interleukin-15 (IL-15) that would be placed in the surgical cavity after tumor removal. IL-15 activates immune cells to recognize and kill residual cancer cells&nbsp;<a href=\"https:\/\/www.drugtargetreview.com\/news\/192939\/organ-on-a-chip-tests-immune-wafer-for-glioblastoma\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. The team is testing this approach using &#8220;glioblastoma-on-a-chip&#8221; technology before moving to human trials.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Organ-on-a-Chip Technology<\/h3>\n\n\n\n<p>This innovative platform creates 3D models of human brain tumors that incorporate immune cells\u2014something traditional cell cultures lack. It allows researchers to test therapies more accurately before reaching patients and could eventually predict individual patient responses to immunotherapy&nbsp;<a href=\"https:\/\/www.drugtargetreview.com\/news\/192939\/organ-on-a-chip-tests-immune-wafer-for-glioblastoma\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Risk Factors and Prevention<\/h2>\n\n\n\n<p>Unlike many cancers,&nbsp;<strong>there are no known lifestyle-related or environmental risk factors<\/strong>&nbsp;for primary brain tumors&nbsp;<a href=\"http:\/\/www.nfcr.org\/cancer-types\/cancer-types-brain-cancer\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><a href=\"https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>. This means there&#8217;s currently no proven way to prevent them.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Known Risk Factors<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Radiation exposure:<\/strong>\u00a0Therapeutic radiation to the head (rare)<\/li>\n\n\n\n<li><strong>Family history:<\/strong>\u00a0Certain inherited syndromes increase risk:\n<ul class=\"wp-block-list\">\n<li>Neurofibromatosis types 1 and 2<\/li>\n\n\n\n<li>Li-Fraumeni syndrome<\/li>\n\n\n\n<li>Tuberous sclerosis<\/li>\n\n\n\n<li>Von Hippel-Lindau disease\u00a0<a href=\"https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p>Factors with uncertain or unproven effects include cell phone use, exposure to vinyl chloride, and certain occupational chemicals&nbsp;<a href=\"http:\/\/www.nfcr.org\/cancer-types\/cancer-types-brain-cancer\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Living with Glioblastoma: Support and Outlook<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Prognostic Factors<\/h3>\n\n\n\n<p>Several factors influence individual prognosis&nbsp;<a href=\"https:\/\/www.cancer.gov\/types\/brain\/hp\/adult-brain-treatment-pdq\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Age:<\/strong>\u00a0Younger patients generally fare better<\/li>\n\n\n\n<li><strong>Tumor genetics:<\/strong>\u00a0IDH mutations and MGMT methylation predict better outcomes<\/li>\n\n\n\n<li><strong>Extent of resection:<\/strong>\u00a0More complete removal improves survival<\/li>\n\n\n\n<li><strong>Performance status:<\/strong>\u00a0Overall health and function at diagnosis<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">The Importance of Clinical Trials<\/h3>\n\n\n\n<p>Given the limited treatment options,&nbsp;<strong>all GBM patients should consider clinical trial participation<\/strong>&nbsp;at every stage of their disease. Trials are investigating:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novel drug combinations<\/li>\n\n\n\n<li>Immunotherapy approaches<\/li>\n\n\n\n<li>Targeted therapies based on tumor genetics<\/li>\n\n\n\n<li>Innovative delivery methods to bypass the blood-brain barrier<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Support Resources<\/h3>\n\n\n\n<p>A glioblastoma diagnosis affects the entire family. Important resources include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neuro-oncology teams<\/strong>\u00a0that include social workers and patient navigators<\/li>\n\n\n\n<li><strong>Support groups<\/strong>\u00a0for patients and caregivers<\/li>\n\n\n\n<li><strong>Palliative care<\/strong>\u00a0to manage symptoms and maintain quality of life<\/li>\n\n\n\n<li><strong>Rehabilitation services<\/strong>\u00a0(physical, occupational, speech therapy)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion: Progress Amidst Challenges<\/h2>\n\n\n\n<p>Glioblastoma remains one of medicine&#8217;s most formidable challenges. Its aggressive nature, treatment resistance, and molecular complexity have thwarted countless therapeutic attempts. Yet the research landscape is shifting.<\/p>\n\n\n\n<p>From immunotherapy timing that makes biological sense to personalized AI-driven treatment selection, from immune-stimulating wafers to targeted vaccines\u2014genuine progress is being made. While we don&#8217;t yet have a cure, each study brings us closer to understanding how to outsmart this deadly cancer.<\/p>\n\n\n\n<p>For patients and families facing this diagnosis, the message is one of cautious hope: research is accelerating, clinical trials are expanding, and the scientific community remains relentlessly committed to finding better treatments.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>References:<\/strong><\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li>National Foundation for Cancer Research. Brain Cancer Statistics and Facts. 2024.<\/li>\n\n\n\n<li>Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.\u00a0<em>ScienceDirect<\/em>. 2025.<\/li>\n\n\n\n<li>Georgetown University Medical Center. Method developed to identify best treatment combinations for glioblastoma.\u00a0<em>EurekAlert!<\/em>\u00a02026.<\/li>\n\n\n\n<li>National Cancer Institute. Central Nervous System Tumors Treatment (PDQ\u00ae). 2025.<\/li>\n\n\n\n<li>Neurology Today. Immunotherapy Administered Before Surgery for Recurrent Glioblastoma Leads to Better Survival Outcomes. 2025.<\/li>\n\n\n\n<li>Drug Target Review. Organ-on-a-chip tests immune wafer for glioblastoma. 2026.<\/li>\n\n\n\n<li>NUHS. Brain Cancer &#8211; Symptoms, Diagnosis, and Treatment. 2025.<\/li>\n\n\n\n<li>Editora da Universidade de Vassouras. Glioblastoma multiforme: What&#8217;s new in relation to established therapeutics? 2025.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>Disclaimer:<\/strong>&nbsp;This article is for educational purposes only and does not constitute medical advice. If you or someone you know is experiencing symptoms of a brain tumor, consult a healthcare provider immediately. Treatment decisions should always be made in consultation with qualified medical professionals.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glioblastoma: Symptoms, Risks &amp; Treatment Guide Learn about glioblastoma, an aggressive form of brain cancer. Discover its symptoms, causes, diagnosis, and treatment options to better understand this serious condition. When we talk about deadly brain cancer, we&#8217;re primarily talking about\u00a0glioblastoma multiforme (GBM)\u00a0\u2014the most aggressive and lethal form of brain cancer in adults. Accounting for approximately\u00a045% of all primary malignant brain tumors, glioblastoma has a devastating prognosis that has remained stubbornly poor despite decades of research\u00a0. The statistics are sobering: the&#8230;<\/p>\n<p class=\"read-more\"><a class=\"btn btn-default\" href=\"https:\/\/blog.mygenericpharmacy.com\/index.php\/2026\/03\/06\/deadly-brain-cancer-understanding-glioblastoma-and-the-fight-for-survival\/\"> Read More<span class=\"screen-reader-text\">  Read More<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1742,909],"tags":[],"class_list":["post-9009","post","type-post","status-publish","format-standard","hentry","category-brain-disease","category-cancer"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/9009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/comments?post=9009"}],"version-history":[{"count":1,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/9009\/revisions"}],"predecessor-version":[{"id":9011,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/posts\/9009\/revisions\/9011"}],"wp:attachment":[{"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/media?parent=9009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/categories?post=9009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.mygenericpharmacy.com\/index.php\/wp-json\/wp\/v2\/tags?post=9009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}